Advertisement

Topics

Eyenovia, Inc. Company Profile

15:32 EST 23rd January 2019 | BioPortfolio


News Articles [22 Associated News Articles listed on BioPortfolio]

Eyenovia enrols first patient for MicroStat programme trials

Eyenovia has enrolled the first patient in a Phase III trial for its MicroStat programme studying pharmacologic mydriasis. The safety and...Read More... The post Eyenovia enrols first patient for Mic...

Eyenovia announces positive results of EYN PG21 clinical trial

Eyenovia, a company developing a pipeline of ophthalmology products using its patented piezo-print technology, has announced positive results of its...Read More... The post Eyenovia announces positive...

Eyenovia Announces Publication of its PG21 Phase II Trial Results

Eyenovia (NASDAQ:EYEN) announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowerin...

Eyenovia Launches Phase 3 Clinical Trial

The company enrolled the first patient in the first of its two Phase 3 trials for its MicroStat program for pharmacologic mydriasis. The post Eyenovia Launches Phase 3 Clinical Trial appeared first on...

Eyenovia Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology ...

Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis

Company on track to initiate Phase III trials in late November NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of opht...

Eyenovia Prices Public Offering of Common Stock

NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of micro...

Eyenovia Reports Third Quarter 2018 Financial Results

NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Eyenovia MiDD Usability Study

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Companies [2 Associated Companies listed on BioPortfolio]

Eyenovia Inc.

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for mic...

Eyenovia, Inc.

More Information about "Eyenovia, Inc." on BioPortfolio

We have published hundreds of Eyenovia, Inc. news stories on BioPortfolio along with dozens of Eyenovia, Inc. Clinical Trials and PubMed Articles about Eyenovia, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eyenovia, Inc. Companies in our database. You can also find out about relevant Eyenovia, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record